Theravance Biopharma Inc (TBPH)

Currency in USD
11.16
-0.02(-0.18%)
Real-time Data·
TBPH Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
TBPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
11.0511.30
52 wk Range
7.4411.88
Key Statistics
Prev. Close
11.18
Open
11.16
Day's Range
11.05-11.3
52 wk Range
7.44-11.88
Volume
35.79K
Average Volume (3m)
263.01K
1-Year Change
42.78%
Book Value / Share
3.36
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TBPH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
17.20
Upside
+54.12%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Theravance Biopharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Theravance Biopharma Inc Company Profile

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Employees
97

Theravance Biopharma Inc Earnings Call Summary for Q1/2025

  • Q1 2025 EPS of -$0.27 missed forecast of -$0.22; revenue of $15.4M slightly exceeded expectations
  • Stock declined 0.9% in aftermarket trading to $9.9 despite 6% YoY revenue growth
  • Strong cash position of $131M with no debt; YUPELRI and TRELEGY showed robust sales growth
  • Company expects improved cash burn in H2 2025 and declining clinical trial costs
  • Analysts project profitability in FY2025 with EPS forecast of $0.26, up from current losses
Last Updated: 08/05/2025, 23:00
Read Full Transcript

Compare TBPH to Peers and Sector

Metrics to compare
TBPH
Peers
Sector
Relationship
P/E Ratio
−9.6x−1.4x−0.5x
PEG Ratio
0.260.090.00
Price/Book
3.4x2.0x2.6x
Price / LTM Sales
8.6x1.5x3.3x
Upside (Analyst Target)
34.2%183.1%43.5%
Fair Value Upside
Unlock31.4%6.9%Unlock

Analyst Ratings

3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 17.20
(+54.12% Upside)

Earnings

Latest Release
May 12, 2025
EPS / Forecast
-0.27 / -0.22
Revenue / Forecast
15.39M / 15.14M
EPS Revisions
Last 90 days

TBPH Income Statement

People Also Watch

5.14
REPL
-6.55%
27.840
SMMT
-2.38%
10.445
COGT
-4.79%
89.28
RYTM
-0.81%
31.54
SRRK
-8.88%

FAQ

What Stock Exchange Does Theravance Biopharma Trade On?

Theravance Biopharma is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Theravance Biopharma?

The stock symbol for Theravance Biopharma is "TBPH."

What Is the Theravance Biopharma Market Cap?

As of today, Theravance Biopharma market cap is 557.51M.

What Is Theravance Biopharma's Earnings Per Share (TTM)?

The Theravance Biopharma EPS (TTM) is -1.19.

When Is the Next Theravance Biopharma Earnings Date?

Theravance Biopharma will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is TBPH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Theravance Biopharma Stock Split?

Theravance Biopharma has split 0 times.

How Many Employees Does Theravance Biopharma Have?

Theravance Biopharma has 97 employees.

What is the current trading status of Theravance Biopharma (TBPH)?

As of 07 Aug 2025, Theravance Biopharma (TBPH) is trading at a price of 11.16, with a previous close of 11.18. The stock has fluctuated within a day range of 11.05 to 11.30, while its 52-week range spans from 7.44 to 11.88.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.